March 30th, 2014
Long-Term Follow-Up from MADIT-CRT: Guideline Implications
Arthur J. Moss, MD
Arthur J. Moss discusses his research group’s study of long-term survival for patients who received cardiac resynchronization therapy with a defibrillator in the MADIT-CRT trial.
March 30th, 2014
MADIT-CRT Long-Term Follow-Up Shows Survival Benefit with CRT-D
Larry Husten, PHD
MADIT-CRT was an influential trial that showed a reduction in heart failure complications — but not mortality — when cardiac resynchronization therapy (CRT) was added to an implantable defibrillator in patients with mild heart failure who also had left bundle-branch block (LBBB). Patients in the trial were followed for 2.4 years, raising questions about the long-term effects […]
March 30th, 2014
First TAVR Comparison Trial Favors Sapien XT Over CoreValve
Larry Husten, PHD
With two devices now approved for transcatheter aortic valve replacement (TAVR), the marketing battle has begun to win the hearts and minds of cardiologists. On Saturday at the ACC, Medtronic gained bragging rights showing the first mortality benefit for its CoreValve device. A similar improvement did not occur in the PARTNER trials with the Edwards […]
March 29th, 2014
TAVR: Are You Impressed Now?
Ajay J Kirtane, MD, SM
Interventionalist Ajay Kirtane offers his perspective on the new randomized trial comparing transcatheter (CoreValve) with surgical aortic valve replacement.
March 29th, 2014
Negative Findings on Renal Denervation for Hypertension: Sweet SYMPLICITY?
Sandeep Mangalmurti, MD, JD
Deepak L. Bhatt, co-principal investigator of the SYMPLICITY HTN-3 trial, discusses the trial’s findings and their implications for clinical practice.
March 29th, 2014
Survival Advantage for TAVR Over Surgery in High-Risk Patients
Larry Husten, PHD
Transcatheter aortic valve replacement (TAVR), which has been slowly and cautiously entering the clinical arena, will probably get a big boost from a new trial showing a significant mortality advtange for TAVR over traditional surgery. Results from the U.S. CoreValve High-Risk Study were presented at the American College of Cardiology in Washington, DC, and published […]
March 29th, 2014
No Benefit Found in First Real Test of Renal Denervation
Larry Husten, PHD
SYMPLICITY HTN-3, the eagerly awaited first rigorous test of renal denervation, shows that the real effect of the novel blood-pressure-lowering technology is dramatically lower than earlier expectations, which had been fueled by data from previous uncontrolled trials. Results of SYMPLICITY HTN-3 were presented at the American College of Cardiology conference in Washington, DC, and published simultaneously […]
March 28th, 2014
Changing My Priorities for ACC.14
Kumar Dharmarajan, MD MBA
A fellow finds that, as his life and career changes, so does his choice of itinerary at ACC.
March 28th, 2014
ACC.14 Headquarters
wpengine
As ACC.14 unfolds, check our Headquarters page for all of our latest coverage!
March 28th, 2014
2014 Atrial Fibrillation Guideline Incorporates New Oral Anticoagulants, Catheter Ablation
Larry Husten, PHD
A new guideline for atrial fibrillation (AF) was released on Friday by the American Heart Association, the American College of Cardiology, and the Heart Rhythm Society. Among other features, the 2014 Guideline for the Management of Patients With Atrial Fibrillation incorporates important new information about the new oral anticoagulants and catheter ablation for the treatment […]